In 1997, the FDA opened the flood gates on direct-to-consumer advertising, thus allowing drugmakers to promote their products on television. DTC has raised awareness of disease and prompted consumers to talk to their doctor about often sensitive topics, but it has also aroused some controversy.

In a recent editorial, Ian Spatz, a former vice president for global health policy at Merck, says doctors feel pressured to prescribe the drugs patients request. And critics say the ads push consumer to ask their doctors for expensive branded drugs, driving up the cost of healthcare.

He suggests drugmakers collaborate on disease-focused campaigns that raise awareness of certain conditions and urge patients to talk to their doctors for treatment options. Doing so would cut companies' advertising budgets, end the ridiculous laundry list of frightening side effects mandated by the FDA, and deliver important information to patients.

While TV proved the dominant medium for DTC in the early 2000s, things might be changing, as Gregory Aston pointed out recently in a blog post for Marketing: Health. In 2010, TV investment fell 17 percent, more than twice the rate of the total category. GSK and six other major pharmaceutical companies significantly reduced their TV investment. Meanwhile, there was a growth seen print (plus 13 percent in 2010, Aston points out). He doesn't see this as a surprise, as it is a tried and tested method to getting the industry's point across.


DTC advertising

Latest Headlines

Latest Headlines

Does pharma spend more on marketing than R&D? A numbers check

So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.

Pharma DTC ad spending sinks 11.5%, a $2B slide from 2006 peak

The bad news for prime-time television and consumer magazines: Pharma's direct-to-consumer advertising dropped by 11.5% last year, to $3.47 billion. The even worse news for digital venues: DTC spend fell by 33%.

Same song, lower budget for pharma's sales force

The more things change, the more they stay the same. According to a new study from Johns Hopkins, that old adage applies to drug marketing.

Testosterone drug sales may be ahead of science

At just under $2 billion a year in sales, the testosterone replacement drug business is small by industry standards, but it is growing as the population ages and sophisticated marketing ramps up.

Big Pharma does lousy job with mobile online sites

While Big Pharma has mastered the art of direct-to-consumer television advertising, and even turned out some pretty impressive websites, when it comes to getting to consumers on their now ubiquitous smartphones, they rate poorly.

Lilly takes the lead in DTC ad spending, surpassing Pfizer

Eli Lilly ($LLY) has overtaken Pfizer ($PFE) in the pharma advertising steeplechase. Cegedim Strategic Data reports that Lilly's spending on direct-to-consumer advertising surpassed Pfizer's in April. And that's a big change. Pfizer has been DTC's big spender for some time.

Top 10 Drug Advertising Spends-- Q1 2012

While the grand party in direct-to-consumer (DTC) advertising may have peaked about 5 years ago, it remains an important method of marketing drugs. In this  FiercePharma special report on the top 10 advertising spends, we have included links to one television spot for each drug.

Pfizer's DTC ad spending dwarfs rivals

Overall, DTC spending has dropped in four of the last 5 years.

As blockbuster drugs fade, so does TV advertising

The DTC juggernaut is weakening. As The New York Times reports, industry spending on TV ads fell by 2% in 2011, the fourth consecutive year of decline. Altogether, TV spending is down 20% from 2007...

FDA finds puppies and moths not guilty of DTC interference

Puppies and beach houses may not be as distracting as the FDA feared. The agency had been studying presentations of risk information in direct-to-consumer advertising to determine how graphics, video...